Phase II Study of Docetaxel and Cisplatin Chemotherapy in 5-Fluorouracil/Cisplatin Pretreated Esophageal Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase II Study of Docetaxel and Cisplatin Chemotherapy in 5-Fluorouracil/Cisplatin Pretreated Esophageal Cancer

Published:2010-12 Issue:6 Volume:33 Page:624-628
ISSN:0277-3732
Container-title:American Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Shim Hyun-Jeong,Cho Sang-Hee,Hwang Jun-Eul,Bae Woo-Kyun,Song Sang-Yun,Cho Sung-Bum,Lee Wan-Sik,Joo Young-Eun,Na Kook-Joo,Chung Ik-Joo

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference25 articles.

1. Global cancer statistics, 2002.;Parkin;CA Cancer J Clin,2005

2. Cancer statistics, 2008.;Jemal;CA Cancer J Clin,2008

3. Esophageal cancer.;Enzinger;N Engl J Med,2003

4. Oesophageal cancer: new developments in systemic therapy.;Ilson;Cancer Treat Rev,2003

5. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer.;Bleiberg;Eur J Cancer,1997

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness analysis of PD-1 inhibitors as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma in China: an economic evaluation based on network meta-analysis;International Journal of Clinical Pharmacy;2024-02-26

2. Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1;Esophagus;2023-03-18

3. Multicenter phase II study of trifluridine/tipiracil for esophageal squamous carcinoma refractory/intolerant to 5-fluorouracil, platinum compounds, and taxanes: the ECTAS study;Esophagus;2022-01-20

4. PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis;BMC Cancer;2021-11-10

5. Quercetin as an anticancer agent: Focus on esophageal cancer;Journal of Food Biochemistry;2020-07-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3